In late October 2025, Chloroform markets turned out to be broadly stable worldwide, indicating a balance between supply and demand following months of price decline. The U.S., South Korea, and Europe remained steady, supported by steady production, sufficient stocks and normal trading activity. Participants described sentiment throughout the industry as neutral with limited arbitrage activity and normal operations for plants. In contrast, China remained under downward pressure as demand from the pharmaceutical and refrigerant industries was weak and high domestic production curbed imports. Demand for the refrigerant R22, a major downstream product of chloroform, declined due to the end of the hot weather season. Overall, the Chloroform market remained steady in the West, but soft in China, indicating range bound conditions into November.
Selenis has effectively manufactured recycled PET chips using terephthalic acid sourced from Circ®, a textile-to-textile recycler based in Virginia. The chip production took place through a series of batches at Selenis' pilot plant in San-Giorgio, Italy. By utilizing inputs recovered from polycotton textile waste, Selenis has created high-quality PET chip, which has been further processed into DTY yarn. This yarn will play a crucial role in product development as Circ prepares for additional capsule launches. Selenis is leveraging the success of this initial collaboration phase and is committed to advancing towards an offtake partnership to support Circ's inaugural industrial facility.
Eduardo Santos, Head of Corporate Strategy at Selenis, remarked that the monomer synthesis showed a performance comparable to virgin terephthalic acid. He expressed optimism about the consistent quality of Circ's monomer output and anticipated future commercial success. Santos pointed out that the Circ partnership complements Selenis's existing mission and goals for a more sustainable textile industry. He further stated their anticipation of expanding upon this collaboration and providing support for Circ's forthcoming commercial production trials.
